This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Charles Marwick

JAMA. 1999;282:1318-1319.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—So severe is the cost-cutting in proposals the US government is considering for reimbursement of hospital outpatient transfusion treatments for a number of disorders that the providers of these services warn they may be discontinued. Hospitals will no longer be able to afford to provide them, warned speakers at a recent meeting of the Health and Human Services (HHS) Advisory Committee on Blood Safety and Availability.

The speakers represented a broad spectrum of the hematology, plasma-derived products, and blood banking communities. At issue is a looming threat by the Health Care Financing Administration (HCFA) to slash reimbursement to hospitals for the provision of blood products, plasma derivatives (including intravenous -globulin and clotting factors), recombinant products, and apheresis services in the outpatient setting. The proposed payment schedule, which would pay hospitals a fraction of the costs of actually providing these services, would initially affect only Medicare beneficiaries but . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?